IFRX InflaRx GmbH: Net earnings per share for the last 12 months

Public company logo of InflaRx NV (IFRX)

InflaRx N.V. (IFRX) management leverages its expertise in inflammation therapy to develop unique antibodies for combating systemic pathologies. The stock price history reflects the EPS TTM trend, which currently stands at -40.90. However, a narrow development pipeline and the costs associated with Vilobelimab trials create financial risks. The company's environmental policy is limited to standard waste disposal and wastewater treatment in its laboratories.

IFRX InflaRx NV Earnings per share for the last twelve months (02/11/2024 - 11/14/2026)

InflaRx GmbH - analytical breakdowns and key metrics (IFRX)

- market value and analyst target forecast:
Stock Quotes InflaRx N.V.|IFRX - Price Target Chart
- company stock capitalization data:
Market Valuation InflaRx NV|IFRX - Real Price to Acquire Entire Company
- book capitalization data:
Book Value per Share InflaRx|IFRX - Company Book Value|Capitalization to Book Value Ratio inflarx.de|IFRX - Company Total Assets
- debt burden and liquidity indicators:
Debt to Capital InflaRx N.V.|IFRX - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient InflaRx N.V.|IFRX - Company Debts|Debt to Book Value Ratio InflaRx NV|IFRX - Company Long-Term Debts|Current Liabilities InflaRx|Quick Liquidity inflarx.de
- earnings and multiples data:
IFRX - Net Profit|Projected Future Earnings InflaRx N.V.|IFRX - Price to Earnings Ratio|Future Price to Earnings Multiple InflaRx N.V.|IFRX - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation InflaRx NV|IFRX - Operating profit before deduction of amortization|Earnings per share for the trailing year InflaRx|IFRX - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months inflarx.de|IFRX - Net earnings per share growth this year|Consensus forecast of earnings per share growth for next year InflaRx N.V.
- revenue and sales details:
IFRX - Company Sales|Company Projected Revenue InflaRx N.V.|IFRX - Market Cap to Revenue|Market Cap to Expected Sales Ratio InflaRx NV
Initial company analysis:InflaRx, IFRX
Core merchandise of InflaRx

Investment risks for InflaRx N.V. (IFRX) are determined by the company's ability to convert antibody development costs into actual profit, as reflected in the year-over-year EPS dynamics (trailing 12 months). This indicator measures the growth rate of net income per share over a rolling year, allowing for an assessment of R&D monetization efficiency amid tight monetary policy and high interest rate pressure.

Competitor analysis for InflaRx N.V.

argenx.com (ARGX) - Net earnings per share for the last 12 months|BioNTech (BNTX) - Earnings per share for the last twelve months|Net earnings per share for the last 12 months Abivax Corp|Net earnings per share for the last 12 months ADMA|Net earnings per share (EPS TTM) Protagonist Corp|Earnings per share for the last twelve months Immunovant, Inc. (IMVT)|kiniksa.com - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) GRFS (Grifols)|Adaptive Biotech (ADPT) - Net earnings per one share for the last twelve months|Celldex - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters Aurinia Corp AUPH|BioCryst (BCRX) - Earnings per share for the last twelve months|Earnings per share for the last 12 months VERA|DNTH (Dianthus Therapeutics, Inc.) - Net earnings per share (EPS TTM)|Pharvaris NV - Earnings per one share for the last 12 months|Earnings per share for the last twelve months AbCellera Corp (ABCL)|Earnings per share for the last twelve months TRML (Tourmaline)|Net earnings per share (EPS TTM) PGEN (Precigen, Inc.)|Net earnings per share (EPS TTM) pharming.com PHAR|NKTR - Earnings per share for the last twelve months|Earnings per share for the trailing year UPB (Upstream Bio, Inc.)|ZBIO (Zenas Biopharma, Inc.) - Net earnings per share for the last 12 months|Earnings per share for the last 12 months IMNM|Net earnings per share for the last 12 months GOSS|KALV: Earnings per share for the trailing year|Earnings per share for the last twelve months Septerna (SEPN)|Pieris Pharma - Earnings per share for the last 12 months|Savara Corp - Net earnings per share for the last 12 months|Net earnings per share for the last four quarters Rigel Corp (RIGL)|ANAB: Net earnings per share for the last 12 months|ATXS: Earnings per share for the last twelve months|ENGN (enGene) - Net earnings per share for the last 12 months|RAPT - Net earnings per share for the last four quarters|JBIO (Aerovate Therapeutics, Inc.) - Net earnings per share (EPS TTM)|Aclaris Therapeutics, Inc (ACRS) - Net earnings per share for the last four quarters|Net earnings per share (EPS TTM) KYTX|TLSA: Earnings per one share for the last 12 months|Earnings per share for the last twelve months Cabaletta Bio CABA|Earnings per share for the trailing year VTYX|THTX: Net earnings per share for the last 12 months|AVTX (Avalo Therapeutics Inc) - Earnings per share for the last 12 months|Eledon Pharmaceuticals (ELDN) - Earnings per share for the last twelve months|Earnings per one share for the last 12 months AGEN (agenusbio.com)|CLYM (Climb Bio) - Net earnings per share (EPS TTM)|ZURA: Earnings per share for the trailing year|Net earnings per share (EPS TTM) ATYR|Net earnings per share (EPS TTM) adagene.com (ADAG)|Earnings per share for the last twelve months Ikena Oncology IMA|Earnings per share for the trailing year STTK|EQ - Earnings per share for the last twelve months|Connect Biopharma (CNTB) - Net earnings per share for the last 12 months|IMUX: Net earnings per share (EPS TTM)|Atara Bio (ATRA) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months XFOR|ACET: Earnings per share for the trailing year|Net earnings per share (EPS TTM) CELU|Net earnings per share for the last four quarters INmune Bio Inc|Earnings per share for the last twelve months Barinthus Bio BRNS|KZR - Net earnings per share for the last 12 months|SABS - Earnings per share for the last twelve months|akaritx.com (AKTX) - Net earnings per share for the last 12 months|ENLV (enlivex.com) - Net earnings per share for the last 12 months|Q32 Bio (QTTB) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months GeoVax Labs Inc|Earnings per share for the last 12 months EDSA (Edesa Biotech Corp)|Net earnings per share (EPS TTM) IBIO|CARM - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) XTLB (XTL Biopharmaceuticals Ltd.)|Net earnings per share for the last four quarters Bolt Biotherapeutics Inc. (BOLT)|HCWB - Earnings per share for the last twelve months|APVO (Aptevo Therapeutics) - Earnings per share for the last 12 months|AIM: Net earnings per share (EPS TTM)|Earnings per one share for the last 12 months ADTX (Aditxt, Inc.)|Earnings per share for the last twelve months GRI Bio|Earnings per share for the last twelve months XRTX|Net earnings per share (EPS TTM) HIND|Net earnings per share (EPS TTM) Revelation Biosciences Corp (REVB)|Earnings per share for the last twelve months Indaptus Therapeutics INDP|Earnings per share for the trailing year SCNI|CALI: Net earnings per share for the last 12 months|AFMD (Affimed) - Earnings per share for the last 12 months|ALLK (allakos.com) - Net earnings per share for the last 12 months|HOOKIPA Pharma - Earnings per share for the trailing year|Earnings per share for the last twelve months IGM Biosciences Inc.|Earnings per share for the last 12 months ITOS (iteostherapeutics.com)|Net earnings per share for the last 12 months OCEA (Ocean Biomedical)|Net earnings per share for the last four quarters TC BioPharm (Holdings) Plc|Third Harmonic Bio, Inc - Net earnings per share for the last 12 months